Dapsone-induced Hemolytic Anemia in Lung Allograft Recipients

Journal of Heart and Lung Transplantation

Volumn 27, Issue 11, 2008, Pages 1198-1202

  Naik, Priyumvada M ^a,b   Lyon III, G Marshall ^b   Ramirez, Allan ^a,b   Lawrence, E Clinton ^a,b   Neujahr, David C ^a,b   Force, Seth ^b   Pelaez, Andres ^a,b  

^a Allergy   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; COTRIMOXAZOLE; CREATININE; CYCLOSPORIN A; DAPSONE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

ADULT; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENZYME BLOOD LEVEL; ERYTHROCYTE TRANSFUSION; FEMALE; HEMOGLOBIN BLOOD LEVEL; HEMOLYSIS; HEMOLYTIC ANEMIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; LABORATORY; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; MALE; MEDICAL LITERATURE; MEDICAL RECORD REVIEW; PNEUMOCYSTIS PNEUMONIA; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; RISK ASSESSMENT; TIME SERIES ANALYSIS;

ANEMIA, HEMOLYTIC; ANTI-INFECTIVE AGENTS; CREATININE; DAPSONE; FEMALE; HEMOGLOBINS; HUMANS; L-LACTATE DEHYDROGENASE; LUNG DISEASES; LUNG TRANSPLANTATION; MALE; POSTOPERATIVE COMPLICATIONS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; TRANSPLANTATION, HOMOLOGOUS;

EID: 54249088812     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2008.07.025     Document Type: Article

References (18)

1. Rodriguez M., and Fishman J.A. Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev 17 (2004) 770-782
2. Dummer J.S., Montero C.G., Griffith B.P., Hardesty R.L., Paradis I.L., and Ho M. Infections in heart-lung transplant recipients. Transplantation 41 (1986) 725-729
3. Gryzan S., Paradis I.L., Zeevi A., et al. Unexpectedly high incidence of Pneumocystis carinii infection after lung-heart transplantation. Implications for lung defense and allograft survival. Am Rev Respir Dis 137 (1988) 1268-1274
4. Gordon S.M., LaRosa S.P., Kalmadi S., et al. Should prophylaxis for Pneumocystis carinii pneumonia in solid organ transplant recipients ever be discontinued?. Clin Infect Dis 28 (1999) 240-246
5. Lee I., Barton T.D., Goral S., et al. Complications related to dapsone use for Pneumocystis jirovecii pneumonia prophylaxis in solid organ transplant recipients. Am J Transplant 5 (2005) 2791-2795
6. Zhu Y.I., and Stiller M.J. Dapsone and sulfones in dermatology: overview and update. J Am Acad Dermatol 45 (2001) 420-434
7. Guidelines for prophylaxis against Pneumocystis carinii pneumonia for persons infected with human immunodeficiency virus. MMWR Morbid Mortal Wkly Rep 38 suppl 5 (1989) 1-9
8. Hughes W.T. Use of dapsone in the prevention and treatment of Pneumocystis carinii pneumonia: a review. Clin Infect Dis 27 (1998) 191-204
9. Masur H. Prevention and treatment of pneumocystis pneumonia. N Engl J Med 327 (1992) 1853-1860
10. Masur H., Kaplan J.E., and Holmes K.K. Guidelines for preventing opportunistic infections among HIV-infected persons-2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. Ann Intern Med 137 (2002) 435-478
11. Bluhm R.E., Adedoyin A., McCarver D.G., and Branch R.A. Development of dapsone toxicity in patients with inflammatory dermatoses: activity of acetylation and hydroxylation of dapsone as risk factors. Clin Pharmacol Ther 65 (1999) 598-605
12. Lant A.F., Hawkins D., et al. A study of the toxicity of dapsone as a PCP prophylactic agent. Balestrini AA ED. Programs and abstracts of the 8th International Conference on AIDS, Amsterdam (1992) 77
13. Beaumont M.G., and MacGregor R.R. Safety of dapsone as PCP prophylaxis in HIV-infected patients with TMP/SMX intolerance. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy (1994), American Society for Microbiology, Orlando, FL 168
14. Sangiolo D., Storer B., Nash R., et al. Toxicity and efficacy of daily dapsone as Pneumocystis jiroveci prophylaxis after hematopoietic stem cell transplantation: a case-control study. Biol Blood Marrow Transplant 11 (2005) 521-529
15. Glanville A.R., Scott A.I., Morton J.M., et al. Intravenous ribavirin is a safe and cost-effective treatment for respiratory syncytial virus infection after lung transplantation. J Heart Lung Transplant 24 (2005) 2114-2119
16. Grossman S.J., and Jollow D.J. Role of dapsone hydroxylamine in dapsone-induced hemolytic anemia. J Pharmacol Exp Ther 244 (1988) 118-125
17. Jollow D.J., Bradshaw T.P., and McMillan D.C. Dapsone-induced hemolytic anemia. Drug Metab Rev 27 (1995) 107-124
18. Bozzette S.A., Finkelstein D.M., Spector S.A., et al. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med 332 (1995) 693-699